In this study, JDM37, the first functional artificial HSP70 activator, was created by computational protein design to break through the limitations of natural JDP, and its modularity provides a new tool for targeting protein-phase-separation-related diseases (e.g. neurodegenerative diseases, cancers), as well as opening a new pathway for elucidating the molecular mechanism of HSP70-JDP. This evidence concerns the gene HSPA1A and cancer.